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ABSTRACT
Objective: To compare the diagnostic outcomes of the
current approach of transrectal ultrasound (TRUS)-
guided biopsy in men with suspected prostate cancer to
an alternative approach using multiparametric MRI
(mpMRI), followed by MRI-targeted biopsy if positive.
Design: Clinical decision analysis was used to
synthesise data from recently emerging evidence in a
format that is relevant for clinical decision making.
Population: A hypothetical cohort of 1000 men with
suspected prostate cancer.
Interventions: mpMRI and, if positive, MRI-targeted
biopsy compared with TRUS-guided biopsy in all men.
Outcome measures:We report the number of men
expected to undergo a biopsy as well as the numbers of
correctly identified patients with or without prostate
cancer. A probabilistic sensitivity analysis was carried out
using Monte Carlo simulation to explore the impact of
statistical uncertainty in the diagnostic parameters.
Results: In 1000 men, mpMRI followed by MRI-
targeted biopsy ‘clinically dominates’ TRUS-guided
biopsy as it results in fewer expected biopsies (600 vs
1000), more men being correctly identified as having
clinically significant cancer (320 vs 250), and fewer men
being falsely identified (20 vs 50). The mpMRI-based
strategy dominated TRUS-guided biopsy in 86% of the
simulations in the probabilistic sensitivity analysis.
Conclusions: Our analysis suggests that mpMRI
followed by MRI-targeted biopsy is likely to result in
fewer and better biopsies than TRUS-guided biopsy.
Future research in prostate cancer should focus on
providing precise estimates of key diagnostic parameters.
INTRODUCTION
Prostate cancer is the most common male
cancer in most developed countries.
Incidence rates have risen rapidly over the
past 15 years, in part due to the increase in
prostate-speciﬁc antigen (PSA) testing. The
use of PSA testing remains controversial as
it lacks both sensitivity and speciﬁcity for the
detection of prostate cancer.1 2 Despite the
high incidence, many men diagnosed with
prostate cancer will not die from the
disease so it is accepted that a distinction
should be made between prostate cancer
that is unlikely to cause harm (‘clinically
insigniﬁcant’ disease) and cancer which, if
untreated, may negatively impact quality of
life or lead to death (‘clinically signiﬁcant’
disease). While there is currently no agreed
threshold of signiﬁcance, most commenta-
tors agree that clinically signiﬁcant disease
should be declared when disease exceeds a
certain volume or is populated by histo-
logical patterns that exhibit poor differenti-
ation (Gleason score).3–5
The optimal strategy for diagnosing clinic-
ally signiﬁcant prostate cancer is the focus of
a rapidly developing body of research. The
Strengths and limitations of this study
▪ There are no clinical studies that directly
compare the standard diagnostic approach using
transrectal ultrasound (TRUS)-guided biopsy in
all men with suspected prostate cancer with an
approach where multiparametric MRI (mpMRI) is
used to select men for biopsy and to guide the
biopsy needle towards a suspicious lesion
against an accepted gold standard.
▪ Our decision analysis brings together emerging
evidence on the diagnostic accuracy of TRUS-
guided biopsy, mpMRI and MRI-targeted biopsies.
▪ A probabilistic sensitivity analysis demonstrates
that the mpMRI-based strategy was most effect-
ive in 86% of the simulations. However this sen-
sitivity analysis did not assess the impact of
structural uncertainties.
▪ This analysis focuses purely on short-term clin-
ical outcomes following different testing options.
Ultimately, the optimal diagnostic strategy for
men with suspected prostate cancer will depend
on the impact on both costs and quality-adjusted
life expectancy.
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standard diagnostic approach for men with suspected
prostate cancer is to offer them a transrectal ultrasound
(TRUS)-guided prostate biopsy taking 10–12 cores.6–8
The ultrasound guidance ensures that the biopsy
needles are guided to zones within the gland which are
considered to have an equal probability of harbouring
disease. An alternative to this is to identify areas of the
prostate that are more likely to contain cancer, and to
sample from these during biopsy. The test that is cur-
rently gaining most favour in conferring this information
is multiparametric MRI (mpMRI).9
An MRI-based approach to diagnosis would require all
men with raised PSA to have an mpMRI. Men who are
negative on mpMRI would receive no further biopsy.
The men with a suspicious lesion on mpMRI would
undergo an MRI-targeted biopsy. During MRI-targeted
biopsy, the biopsy needle can be directed by the clin-
ician using prior mpMR images and real-time ultrasound
(‘visual’ or ‘cognitive registration’), by using assistive
technology that digitally overlays the target information
derived from the mpMRI directly onto the ultrasound
image (‘computer-aided registration’ or ‘image fusion’)
or the biopsy can be performed within the MR scanner
itself (‘in-bore biopsy’ or ‘MR-guided MR biopsy’).
Irrespective of the image-guided technique, an
mpMRI-based approach to diagnosis has three potential
advantages. First, patients with no lesion on mpMRI
could avoid a prostate biopsy. Second, patients with clin-
ically insigniﬁcant disease would avoid diagnosis and
subsequent inappropriate treatment which carries risk of
side effects and no beneﬁt in terms of survival. Third,
using mpMRI for targeting may improve the detection
of clinically signiﬁcant cancers and improve risk
stratiﬁcation.
The UK’s National Institute for Health and Care
Excellence (NICE) has recently acknowledged the utility
of mpMRI, but stopped short of a recommendation to
offer prebiopsy mpMRI to all men.7 It remains contro-
versial partly due to doubts about the performance and
reproducibility of mpMRI. Despite this, many providers
have adopted an image-guided biopsy approach in
response to a man presenting with an elevated PSA.10
We summarise what can be understood from recently
emerging evidence in a format that is relevant for clin-
ical decision making. We carried out a decision analysis
to compare a simpliﬁed version of the current standard
diagnostic approach (TRUS-guided biopsy) with an
approach where mpMRI is used to select men for biopsy
and to guide the biopsy needle towards the area of sus-
pected cancer. We estimate the number of biopsies that
could be avoided with prebiopsy mpMRI and the
number of correctly identiﬁed patients with and without
clinically signiﬁcant prostate cancer.
METHODS
Decision analysis
We used a decision tree to compare the standard diag-
nostic pathway (TRUS-guided biopsy for all) with a new
pathway (mpMRI for all, then MRI-targeted biopsy if
positive). The tree, presented in ﬁgure 1, was evaluated
to reveal the expected outcomes associated with each
option, for a hypothetical cohort of 1000 men by multi-
plying the prevalence estimates of our target condition
by sensitivity and speciﬁcity estimates of the diagnostic
tests. The test accuracy estimates used to populate the
decision tree were derived from recent studies which
reported data that reﬂected the conditional nature of
the parameters and used an appropriate reference
test.11 12 All of these data are limited in some way, but
assumptions were made so that any biases would favour
the current diagnostic approach.
Target population
The target population for the decision analysis was men
with increased serum PSA levels or abnormal ﬁndings
on digital rectal examination who had never had a pros-
tate biopsy.
Clinically significant disease
For our base-case analysis we deﬁned clinically signiﬁ-
cant disease according to widely used, and arguably
somewhat conservative, criteria: a minimum volume of
0.2 cc or cell differentiation corresponding to a Gleason
Figure 1 Structure of the decision tree.
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score of 3+4 or higher.13 The prevalence of clinically sig-
niﬁcant disease in our target population is uncertain,
but we estimated it to be 50% of all men with suspected
prostate cancer, based on a prospective analysis of men
undergoing a ﬁrst prostate biopsy.14 The remaining 50%
are assumed to have clinically insigniﬁcant disease or no
cancer. We varied the prevalence of clinically signiﬁcant
disease in a sensitivity analysis.
TRUS-guided biopsy
The gold standard used to establish the presence or
absence of clinically signiﬁcant disease—whole-mount
pathological data—is usually only available for men who
test positive and then go on to have radical
surgery.7 11 15 Therefore, we used data from a study
which carried out computer simulations to estimate the
performance characteristics of TRUS-guided biopsy by
comparing them to reconstructed whole-mount path-
ology obtained from patients undergoing surgery for
bladder cancer, which revealed that they also had pros-
tate cancer.16 The spectrum of disease in this sample
population is likely to include more early-stage disease
than would be expected in an unscreened UK popula-
tion, and thus this bias will favour the current diagnostic
approach.
The sensitivity of TRUS-guided biopsy, when criteria
proposed by Epstein were used to interpret the diagnos-
tic result, was approximately 50%.16 According to
Epstein et al,13 a biopsy result is positive for signiﬁcant
cancer if the maximum cancer core length from biopsy
is at least 3 mm or if the Gleason score is 3+4 or higher.
The corresponding speciﬁcity of TRUS-guided biopsy
was estimated to be approximately 90%, which repre-
sents the proportion of men correctly identiﬁed with
insigniﬁcant disease (men with no prostate cancer were
not included in the Lecornet et al16 study population).
mpMRI and MRI-targeted biopsy
We estimated the diagnostic accuracy for the MRI-based
strategy by combining the test accuracy estimates for
mpMRI and MRI-targeted biopsy. A recent systematic
review of the literature revealed two studies on mpMRI in
biopsy-naïve men with suspected prostate cancer.11 17 18
Only one of these studies reported data at the level of
detail required to estimate sensitivity and speciﬁcity of
mpMRI: a large study involving 555 men which compared
prebiopsy mpMRI results with TRUS-guided biopsy and/
or MRI-targeted biopsy as a proxy for true disease
status.17 We used these data to estimate the sensitivity of
mpMRI at 80% and the speciﬁcity at 60%. A more recent
study shows these values may in fact underestimate the
performance of mpMRI.14
The accuracy of MRI-targeted biopsy was taken from a
study that compared MRI-targeted biopsy with cognitive
registration to 20-sector template-prostate mapping.19
This study was used since all men in the study population
had a lesion on mpMRI and therefore allowed us to
capture the sequential nature of the diagnostic approach.
The study showed that when the biopsies were classiﬁed
according to the Epstein criteria, the sensitivity was
approximately 80% and the speciﬁcity 80%.19 The speci-
ﬁcity that this study reported for the MRI-targeted biopsy
is lower than our estimate of the speciﬁcity of
TRUS-guided biopsy (90%).19 However, the use of
MRI-targeting instead of TRUS-guided biopsy should
have no impact on men without clinically signiﬁcant
disease, and therefore we assumed that MRI-targeted
biopsy should be as good as—but not better than—
TRUS-guided biopsy at correctly identifying men without
clinically signiﬁcant prostate cancer. We therefore used
90% as the speciﬁcity estimate for MRI-targeted biopsy in
the decision analysis, the same as that of TRUS-guided
biopsy. We assessed the impact this had on the overall
diagnostic results in a sensitivity analysis.
Sensitivity analysis
We carried out a one-way sensitivity analysis by varying
the prevalence of clinically signiﬁcant disease from 0 to
1, keeping all other variables constant. This sensitivity
analysis was intended to demonstrate the extent to
which the optimal diagnostic strategy depends on the
prevalence of clinically signiﬁcant disease. We also
carried out two sensitivity analyses to assess the impact of
speciﬁc test performance estimates of the mpMRI-based
strategy on overall diagnostic outcomes. In the ﬁrst scen-
ario (scenario i) we used a pooled estimate of mpMRI
test performance from a recent meta-analysis (mpMRI
sensitivity 74%, mpMRI speciﬁcity 88%).20 In the second
scenario (scenario ii) we investigated the impact of our
assumption that MRI targeting has no impact on men
without clinically signiﬁcant disease (by using a speciﬁ-
city of 80% for MRI-targeted biopsy as reported by
Kasivisvanathan et al19 rather than our base case estimate
of 90%).
Although these sensitivity analyses provide some
insight into the speciﬁc impact of individual parameters,
the estimates used to describe the performance of all
the diagnostic tests are associated with signiﬁcant uncer-
tainties. Therefore, to assess the robustness of our
results, we performed a probabilistic sensitivity analysis
using Monte Carlo simulation by varying the sensitivities
and speciﬁcities of the three tests (TRUS-guided biopsy,
mpMRI and MRI-targeted biopsy) simultaneously over
2000 iterations, sampling from beta distributions to char-
acterise the uncertainty in the test accuracy data (see
table 1). We determined the beta distributions by assum-
ing that the sensitivities and speciﬁcities were observed
in populations consisting of 50 men with and 50 men
without clinically signiﬁcant disease. We substantially
widened the distributions (by assuming a small popula-
tion of men) in order to increase the uncertainty asso-
ciated with the test performance parameters. We
ignored the correlation between sensitivity and speciﬁ-
city and kept the disease prevalence constant at 50%.
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RESULTS
The decision tree estimated that the use of
TRUS-guided biopsy in a hypothetical cohort of 1000
men with suspected prostate cancer—and an estimated
50% prevalence of clinically signiﬁcant disease—would
result in 300 positive and 700 negative biopsy results,
which would correctly identify 250 men with clinically
signiﬁcant prostate cancer and 450 men without the
disease (table 2). It follows that 250 men with signiﬁcant
prostate cancer would be missed by TRUS-guided biopsy
and 50 men who do not have signiﬁcant prostate cancer
would wrongly receive a diagnosis.
The use of mpMRI and MRI-targeted biopsy in the
same cohort would result in 600 men undergoing a
prostate biopsy with 340 positive and 260 negative
biopsy results (table 2). This strategy would correctly
identify 320 men as having signiﬁcant prostate cancer
and 480 without the disease. In other words, the use of
the mpMRI-based strategy would fail to diagnose signiﬁ-
cant cancer in 180 men (500–320), which is the result
of signiﬁcant prostate cancers that were missed by
mpMRI in addition to signiﬁcant cancers that were iden-
tiﬁed on mpMRI but were missed by MRI-targeted
biopsy. Twenty men (500–480) who do not have clinic-
ally signiﬁcant prostate cancer would wrongly receive a
diagnosis.
mpMRI followed by MRI-targeted biopsy can be said
to ‘clinically dominate’ TRUS-guided biopsy as the strat-
egy results in fewer expected biopsies (600 vs 1000),
more men being correctly identiﬁed as having clinically
signiﬁcant disease (320 vs 250), and fewer men being
falsely identiﬁed with the disease (20 vs 50).
Figure 2 provides a visual representation of the
one-way sensitivity analysis showing the total number of
people receiving the wrong diagnosis (the sum of the
number of patients with a false-positive or a false-
negative result) as a function of the prevalence of clinic-
ally signiﬁcant disease. The mpMRI-based approach
resulted in a lower number of patients wrongly diag-
nosed than with TRUS-guided biopsy for all men, at all
prevalence rates. Below a prevalence of 5%, doing
nothing is the ‘optimal’ strategy as it leads to the lowest
number of men with the wrong diagnosis. Above a
prevalence of 70%, treating all men is optimal.
Table 3 demonstrates that assuming a sensitivity of
74% and a speciﬁcity of 88% as estimates of the test per-
formance of mpMRI (instead of a sensitivity of 80% and
a speciﬁcity of 60% used in the base case analysis) found
that the mpMRI-based strategy resulted in far fewer
biopsies than our base case estimation (430 instead of
600), but slightly worse diagnostic outcomes for men
with signiﬁcant disease (296 correctly identiﬁed instead
of 320), which was still better than the current standard
of care (250 correctly identiﬁed). Table 3 also shows that
using a lower speciﬁcity for MRI-targeted biopsy (80%
instead of 90%) resulted in 40 men (instead of 20)
without clinically signiﬁcant disease wrongly identiﬁed as
having signiﬁcant cancer, but this is still less than the 50
men who would be wrongly identiﬁed with the standard
diagnostic approach using TRUS-guided biopsy alone.
Table 1 Diagnostic accuracy estimates of TRUS-guided biopsy, mpMRI and MRI-targeted biopsy used in the base case
analysis
Index test Sensitivity Specificity Reference test Source and patient population
TRUS-guided
biopsy
50%
(16/34
patients, 95%
CIs 27% to
73%)
α=25, β=25
90%
(57/62 patients, 95% CIs
78% to 97%)
α=45, β=5
Whole-mount pathology Lecornet et al16: simulated
biopsy results on digitally
reconstructed prostates of 96
men who had undergone
surgery for bladder cancer
which revealed prostate cancer
mpMRI 80%
(252/302, 95%
CIs 66% to
90%)
α=40, β=5
60%
(154/253 patients, 95% CIs
45% to 76%)
α=30, β=20
TRUS-guided extended
systematic biopsies (10–12
core) plus two targeted
biopsies for those with any
area suspicious on mpMRI
(score ≥3)
Haffner et al17: 555 men with
suspected localised prostate
defined as raised PSA of >3–
4 ng/mL and/or abnormal DRE
with no clinical or biological
suspicion of stage T>3 or
metastases and had no prior
biopsy
MRI-targeted
biopsy
80%
(94/121
patients, 95%
CIs 66% to
90%)
α=40, β=10
90%
Assumed to be equivalent to
the specificity of
TRUS-guided biopsy, (57/62
patients, 95% CIs 78%
to 97%) α=45, β=5
20 sector-TPM Kasivisvanathan et al19: 182
men who had a suspicious
lesion on mpMRI; 78 of whom
were biopsy naive, 32 had a
prior negative biopsy and 72 had
a prior positive biopsy
TRUS, transrectal ultrasound; TPM, template mapping biopsy; mpMRI, multiparametric MRI; MRI-TB, MRI-targeted biopsy. Data inputs were
rounded to the nearest 5%. Beta distributions were estimated using the integer form in Excel according to the parameters α and β.
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When the sensitivities and speciﬁcities of the three
tests were varied simultaneously in 2000 simulations for
the probabilistic sensitivity analysis, the diagnostic
approach using mpMRI and MRI-targeted biopsy clinic-
ally dominated 86% of the simulations, whereas
TRUS-guided biopsy dominated in 0.8% of
the simulations. Within the remaining 13.2% of simula-
tions, the choice between the mpMRI-based strategy
and TRUS-guided biopsy is not clear as there was a
‘trade-off’ between outcomes. That is, either the
mpMRI-based strategy correctly identiﬁed more men
with clinically signiﬁcant cancer but fewer men without
clinically signiﬁcant disease than TRUS-guided biopsy, or
vice versa.
DISCUSSION
Our decision analysis suggests that mpMRI of the pros-
tate followed by MRI-targeted biopsy if positive could
result in fewer and better biopsies than a strategy using
Table 2 Details of calculations and results of the decision analysis for a cohort of 1000 men comparing TRUS-guided biopsy
with mpMRI and MRI-targeted biopsy
TRUS-guided biopsy for all mpMRI then MRI-targeted biopsy
Number of biopsies 1000
(all men)
600
= P(MRI+|D+)+P(MRI+|D−)
= (MRIsens*prev*no_in_cohort)+
((1-MRIspec)*(1-prev)*no_in_cohort))
= (0.8*0.5*1000)+((1−0.6)*(1−0.5)*1000)
Patients with clinically significant
cancer and correctly identified
(true positive)
250
=P(TRUS+|D+)
=TRUSsens*prev*no_in_cohort
=0.5*0.5*1000
320
=P(MRI+|D+).P(MRITB+|D+)
=MRIsens*MRITBsens*prev*no_in_cohort
=0.8*0.8*0.5*1000
Patients with clinically significant
cancer and wrongly identified
(false negative)
250
=p(TRUS−|D+)
=(1-TRUSsens)*prev*no_in_cohort
=(1−0.5)*0.5*1000
180
=P(MRI−|D+)+P(MRI+|D+).P(MRITB−|D+)
=((1-MRIsens)*prev*no_in_cohort) +
(MRIsens*(1-MRITBsens)*prev*no_in_cohort)
=((1−0.8)*0.5*1000)+(0.8*(1−0.8)*0.5*1000)
Patients with insignificant
prostate cancer or no prostate
cancer and correctly identified
(true negative)
450
=P(TRUS−|D−)
=TRUSspec *(1-prev)*no_in_cohort
=0.9*(1−0.5)*1000
480
=P(MRI−|D−)+P(MRI+|D−).P(MRITB−|D−)
=(MRIspec*(1-prev)*no_in_cohort) +
((1-MRIspec)*MRITBspec*(1-prev)*no_in_cohort)
=(0.6*(1−0.5)*1000)+((1−0.6)*0.9*(1−0.5)*1000)
Patients with insignificant
prostate cancer or no prostate
cancer and wrongly identified
(false positive)
50
=P(TRUS+|D−)
=(1-TRUSspec)*(1-prev)* no_in_cohort
=(1−0.9)*0.5*1000
20
=P(MRI+|D−).P(MRITB+|D−)
=(1-MRIspec)*(1-MRITBspec)*(1-prev)*no_in_cohort
=(1−0.6)*(1−0.9)*(1−0.5)*1000
‘prev’ – prevalence; ‘no_in_cohort’ – number of men in cohort; ‘TRUSsens’ – sensitivity of TRUS-guided biopsy; ‘TRUSspec’ – specificity of
TRUS-guided biopsy; ‘MRIsens’ – sensitivity of mpMRI; ‘MRIspec’ – specificity of mpMRI; ‘MRITBsens’ – sensitivity of MRI-targeted biopsy;
‘MRITBspec’ – specificity of MRI-targeted biopsy.
Figure 2 One-way sensitivity
analysis showing the expected
number of patients with wrong
diagnoses according to the
prevalence of clinically significant
disease in a cohort of 1000 men.
See text for further explanation.
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only TRUS-guided biopsy. The results suggest that the
mpMRI-based strategy could reduce the number of biop-
sies by about one-third (600 compared to 1000 biopsies),
increase the number of men identiﬁed with clinically sig-
niﬁcant cancer by about 30% (320 compared to 250
patients), and reduce the number of men falsely identi-
ﬁed with the disease by 60% (20 compared to 50).
These results are in line with those of recent clinical
studies comparing similar strategies, albeit not against a
gold standard of pathology or template biopsy.21 22
When we accounted for uncertainty in the sensitivity
and speciﬁcity estimates of the three diagnostic tests, we
found that the dominance of the mpMRI-based strategy
was robust. However, the probabilistic sensitivity analysis
did not assess the impact of inherent ‘structural’ uncer-
tainties, such as the ongoing debate about the deﬁnition
of clinically signiﬁcant cancer, various diagnostic thresh-
olds used to decide whether mpMRI or biopsy results
are positive or negative, and the use of imperfect gold-
standard tests.
NICE has recently updated its guidance on the diag-
nosis and management of men with prostate cancer.7
Our estimate of the sensitivity of 50% for TRUS-guided
biopsy is close to the estimate of 45% used in its ana-
lysis.7 However, we estimated the speciﬁcity of the
TRUS-guided biopsy to be 90%, while NICE assumed it
to be 100%. While both of these speciﬁcity estimates are
somewhat speculative, we believed that the speciﬁcity
estimate needed to reﬂect that patients who have clinic-
ally insigniﬁcant prostate cancer may have biopsy results
that are interpreted as being suggestive of clinically
signiﬁcant cancer. We also assumed that this ‘error’ is as
likely with TRUS-guided as with MRI-targeted biopsies
and therefore we used the same false-positive rate for
TRUS-guided and for MRI-targeted biopsies. In addition
we used data on the test accuracy of MRI-targeted biopsy
from a study which used visual registration techniques. It
has been suggested that computer-aided registration
techniques may be more accurate,7 although recent ran-
domised controlled trial (RCT) data showed no statistic-
ally signiﬁcant difference in detection rates.23
The results of our analysis are based on a simpliﬁca-
tion of the choices facing urologists in the diagnosis of
prostate cancer. In their evaluation, NICE considered a
strategy of mpMRI and biopsy for all men, including tar-
geted biopsies for all men with a lesion on mpMRI. This
perhaps highlights the reticence of healthcare profes-
sionals to do ‘less’ rather than ‘more’, which may be
inﬂuenced by concern over medical liability. A major
challenge therefore will be the implementation of a
strategy that requires a negative diagnostic test result to
be established and then followed by no immediate
further investigation. New guidelines based on the
results of forthcoming RCTs (such as PROMIS) and
expert consensus may be required to avoid a ‘creep’ in
the numbers of unnecessary biopsies.24
In this analysis we focused purely on short-term clin-
ical outcomes following different testing options.
Ultimately, however, the optimal diagnostic strategy for
men with suspected prostate cancer will depend on the
impact on costs and quality-adjusted life expectancy. The
cost of the diagnostic procedures may in fact be about
Table 3 Results of sensitivity analyses in a cohort of 1000 men
Scenario Base case analysis
Scenario i
(mpMRI sensitivity 74%,
specificity 88%)
Scenario ii
(MRI-targeted biopsy
sensitivity 80%,
specificity 80%)
Strategy
TRUS-guided
biopsy for all
mpMRI then
MRI-targeted
biopsy
TRUS-guided
biopsy for all
mpMRI then
MRI-targeted
biopsy
TRUS-guided
biopsy for all
mpMRI then
MRI-targeted
biopsy
Number of biopsies 1000 600 1000 430 1000 600
Patients with clinically
significant cancer and correctly
identified (true positive)
250 320 250 296 250 320
Patients with clinically
significant cancer and wrongly
identified (false negative)
250 180 250 204 250 180
Patients with insignificant
prostate cancer or no prostate
cancer and correctly identified
(true negative)
450 480 450 494 450 460
Patients with insignificant
prostate cancer or no prostate
cancer and wrongly identified
(false positive)
50 20 50 6 50 40
mpMRI, multiparametric MRI; TRUS, transrectal ultrasound.
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the same for the two diagnostic strategies. If all men
receive an mpMRI (£200 in 2011–2012 UK National
Health Service (NHS) prices) and 60% of these men
also receive a biopsy (£540 in 2011–2012 UK NHS
prices) the mpMRI-based strategy will result in an
average cost of £524 per man, assuming that a
TRUS-guided biopsy and MRI-targeted biopsy are
equivalent in cost.25 This compares to £540 per man
with a TRUS-guided biopsy. Of course, the true costs of
the two strategies include the long-term costs and conse-
quences of further investigations and treatments which
need to be taken into account in future economic mod-
elling. Initial estimates from a published economic
evaluation suggest that an mpMRI-based strategy is likely
to be highly cost effective in the Netherlands,26 although
uncertainties, particularly around long-term health out-
comes, remain.27
Despite the complexity of the downstream pathways,
estimates of diagnostic performance and disease preva-
lence will be key drivers of the clinical and cost effective-
ness of the whole of prostate cancer care. Systematic
reviews of the prostate biopsy and imaging literature
have revealed a large number of small studies charac-
terised by poor reporting and important biases.7 11 12 15
In our analysis we only used very recently published
studies that capture the emerging evidence on how well
TRUS-guided biopsy, mpMRI and MRI-targeted biopsy
perform and estimate disease prevalence. Future
research efforts in prostate cancer need to focus on pro-
viding accurate and precise estimates of these para-
meters. Studies need to consistently distinguish between
signiﬁcant and insigniﬁcant cancer, represent the
sequential nature of diagnostic tests and should adhere
to high standards of reporting such as the START guide-
lines for MRI.28 29 Without these studies, it will be hard
to accurately evaluate the role of targeted biopsy or any
new strategy for diagnosing prostate cancer in future.
CONCLUSIONS
Our analysis suggests that mpMRI followed by
MRI-targeted biopsy may result in fewer and better biop-
sies than TRUS-guided biopsy for all men. We found
that the mpMRI-based strategy correctly identiﬁed more
men with signiﬁcant prostate cancer and also correctly
identify more men without the disease in 86% of the
simulations in our probabilistic sensitivity analysis.
Estimates of disease prevalence and diagnostic perform-
ance will be key drivers of a full economic analysis, so
research efforts should focus on providing precise esti-
mates of these crucial parameters.
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